# Chiricaspi (Croton palanostigma)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/chiricaspi-croton-palanostigma
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** South American
**Also Known As:** Croton palanostigma, Sangre de Grado (related species grouping), Dragon's Blood (Amazonian type), Chiricaspi latex plant

## Overview

Chiricaspi contains taspine, clerodane and labdane diterpenoids, proanthocyanidins, and flavonoids such as quercetin that drive its bioactivity through microtubule disruption, [COX-2](/ingredients/condition/inflammation) inhibition, and [reactive oxygen species](/ingredients/condition/antioxidant) scavenging. Preclinical cell-line studies show its red latex induces G2/M phase arrest and apoptosis in cancer cells via chromatin condensation and non-functional microtubule assembly, though no human clinical trial data currently substantiate these effects.

## Health Benefits

- **Anticancer Activity (Preclinical)**: The red latex of C. palanostigma disrupts microtubule polymerization and blocks cancer cells in the late G2 phase, leading to chromatin condensation and apoptotic cell death; this effect has been demonstrated in vitro but not yet in human trials.
- **Wound Healing Support**: Taspine, a key alkaloid in Croton red latex, exerts cytokine-modulating and tissue-regenerative properties that have supported traditional use for wound closure and fracture recovery across multiple Croton species including C. lechleri.
- **Anti-Inflammatory Effects**: Flavonoids including quercetin suppress [pro-inflammatory cytokine](/ingredients/condition/inflammation) cascades and inhibit COX-2 enzyme activity, potentially reducing local and systemic inflammatory signaling as demonstrated in Croton genus extracts.
- **Antioxidant Protection**: Proanthocyanidins, catechins, and gallic acid-type phenolics found in Croton extracts scavenge [reactive oxygen species](/ingredients/condition/antioxidant) and chelate redox-active metals, contributing to cellular protection against oxidative stress in related species studies.
- **[Antimicrobial](/ingredients/condition/immune-support) Properties**: Quercetin isolated from Croton species demonstrates measurable minimum inhibitory concentration (MIC) activity against Gram-positive bacteria such as Bacillus species, suggesting utility against specific bacterial pathogens.
- **Apoptosis Induction via [Mitochondrial](/ingredients/condition/energy) Pathway**: Beyond microtubule disruption, Croton genus alkaloids and flavonoids downregulate BCL-2 anti-apoptotic protein expression and promote mitochondrial-dependent apoptotic signaling, offering a complementary mechanism of cancer cell elimination.
- **Traditional Rheumatic and Musculoskeletal Relief**: In Andean ethnomedicine, Chiricaspi latex is applied topically for rheumatic pain, with diterpenoids such as clerodanes and labdanes postulated as contributors to local anti-inflammatory and analgesic effects, though this remains pharmacologically unvalidated.

## Mechanism of Action

The red latex of Croton palanostigma exerts anticancer effects primarily by perturbing microtubule dynamics: bioactive compounds interfere with tubulin polymerization, disrupt adhesion complexes, and prevent reassembly of functional mitotic spindles, causing arrest in the late G2/M phase followed by chromatin condensation, nuclear contraction, and apoptotic cell death. Taspine contributes to cytotoxicity and [anti-inflammatory](/ingredients/condition/inflammation) activity by modulating cell adhesion molecules and suppressing inflammatory mediator release, while flavonoids such as quercetin inhibit COX-2 transcription and scavenge [reactive oxygen species](/ingredients/condition/antioxidant) through direct radical quenching and metal chelation. Diterpenoids of the clerodane and labdane classes may modulate transcription factor activity and membrane receptor signaling, with one constituent, pachypodol, demonstrating enzyme inhibition of [mitochondrial](/ingredients/condition/energy) ATP synthase at an IC50 of approximately 51 µM in preclinical assays, raising both therapeutic and toxicological considerations. Proanthocyanidins and catechins amplify antioxidant responses through Nrf2-pathway-associated mechanisms inferred from related Croton species research, collectively producing a multi-target bioactive profile.

## Clinical Summary

No formal clinical trials have been conducted for Chiricaspi (Croton palanostigma) in any therapeutic indication as of the available literature. The closest proxy evidence derives from preclinical studies on the red latex demonstrating in vitro anticancer mechanisms and from ethnobotanical observational reports of wound and fracture management in Amazonian communities, neither of which constitutes controlled clinical evidence. Outcomes measured in preclinical settings include cell-cycle phase distribution, apoptosis rates, and microtubule morphology, but effect sizes have not been reported in standardized clinical metrics. Regulatory and research bodies consistently note that pharmacokinetic profiling, toxicity studies, and phase I safety trials are prerequisite steps before any clinical confidence can be established for this ingredient.

## Nutritional Profile

Croton palanostigma is not consumed as a food and does not possess a characterized macronutrient or micronutrient profile in the conventional dietary sense. Its phytochemical composition, as inferred from preclinical extracts and genus-level studies, includes flavonoids (quercetin, myricetin-3-O-rhamnoside, catechin) at approximately 3.5 µg/mL in standardized extracts of related species, phenolic compounds including gallic acid and catechins at approximately 43 µg/mL in certain fractions, and proanthocyanidins that may constitute over 90% of the dry-weight phenolic content in concentrated latex. Alkaloids, principally taspine, and diterpenoids of the clerodane and labdane structural classes are present but not quantified with precision in published assays for this specific species. Bioavailability data are absent; lipophilic diterpenoids are expected to require emulsification or lipid co-ingestion for oral absorption, while water-soluble flavonoids and phenolics may be subject to hepatic first-pass [metabolism](/ingredients/condition/weight-management), based on class-level pharmacokinetic principles.

## Dosage & Preparation

- **Traditional Fresh Latex (Topical)**: Direct application of freshly harvested red latex to wounds, skin lesions, or affected joints; no standardized volume or frequency established.
- **Ethanol or Acetone Extract (Research Grade)**: Used in preclinical cell-line studies at concentrations typically ranging from 3.5 to 43 µg/mL for flavonoid and phenolic fractions; no human dose established.
- **Aqueous Bark Extract**: Related Croton species are optimally extracted in water at approximately 35°C for 90 minutes to maximize phenolic yield; this method is referenced in ethnobotanical literature but not standardized for C. palanostigma.
- **No Commercial Supplement Form Available**: No capsule, tablet, tincture, or standardized extract product for Chiricaspi is currently documented in commercial supplement markets as of available data.
- **Standardization**: No standardization percentages for taspine, proanthocyanidins, or specific diterpenoids have been established or validated for C. palanostigma extracts.
- **Timing and Effective Dose**: Effective human doses are entirely unknown; traditional use is empirical and not dose-quantified.

## Safety & Drug Interactions

Safety data for Croton palanostigma is limited to preclinical observations and anecdotal ethnobotanical reports; no formal toxicology studies, maximum tolerated dose assessments, or human adverse event surveillance data have been published for this species. The presence of phorbol esters, a class of diterpenoids documented in various Croton species, constitutes a significant toxicological concern, as phorbol esters are potent protein kinase C activators and tumor promoters at sustained exposures, and their concentration in C. palanostigma has not been adequately characterized. The enzyme inhibition activity of constituent pachypodol against mitochondrial ATP synthase at IC50 51 µM raises potential cytotoxic and metabolic interference risks, particularly with concurrent use of medications affecting [mitochondrial function](/ingredients/condition/energy), anticoagulants, or cytochrome P450-metabolized drugs, though specific pharmacokinetic interaction data are not available. Pregnant and lactating individuals should avoid this ingredient entirely given the absence of safety data and the known pro-apoptotic and cytotoxic activities of the latex; use should be limited to research or traditional contexts with full acknowledgment of uncharacterized risk.

## Scientific Research

The current evidence base for Croton palanostigma consists entirely of preclinical in vitro studies; no peer-reviewed human clinical trials have been published specifically for this species or the traditional Chiricaspi preparation. Cell-line studies document G2/M phase arrest and apoptosis in treated cancer cells, providing mechanistic proof-of-concept, but absence of in vivo pharmacokinetic data, dose-response curves, and toxicity profiles substantially limits translational confidence. Evidence from the closely related species Croton lechleri (Sangre de Grado) provides partial context, including folk-medicine and informal clinical observations of wound and fracture healing without reported side effects, and preclinical melanoma antiproliferation data, but direct extrapolation to C. palanostigma is not scientifically validated. The overall quality of evidence is rated low to very low by contemporary standards, with no randomized controlled trials, no quantified effect sizes such as Cohen's d, and no published sample-size-powered studies available for this ingredient.

## Historical & Cultural Context

Chiricaspi has been utilized by indigenous Amazonian communities of Peru and Ecuador for centuries as a primary wound-healing and bone-fracture remedy, with the characteristic red latex of the bark regarded as a potent healing sap analogous to blood, a symbolism shared across the broader Amazonian Croton pharmacopoeia often called 'Sangre de Grado' or dragon's blood. In Andean and upper Amazonian ethnomedicine, the plant holds significance not only for topical wound care but also as a treatment for rheumatic and musculoskeletal pain, reflecting deep integration of diterpenoid-rich Croton species into regional healing traditions. Preparation has historically centered on direct bark incision to collect fresh latex, which is applied undiluted to wounds, or diluted in water for internal use in certain community traditions, though the latter application raises safety considerations that have not been formally evaluated. The name 'Chiricaspi' derives from Quechua linguistic roots, reflecting cultural integration into the highland and transitional forest communities of the Andean-Amazonian interface, and the species is referenced in regional botanical surveys and ethnopharmacological compilations documenting South American medicinal flora.

## Synergistic Combinations

Based on shared [anti-inflammatory](/ingredients/condition/inflammation) and [antioxidant](/ingredients/condition/antioxidant) mechanisms, Chiricaspi extracts may theoretically exhibit additive or synergistic effects when combined with other polyphenol-rich Amazonian botanicals such as Cat's Claw (Uncaria tomentosa), whose oxindole alkaloids also modulate NF-κB and COX-2 pathways, potentially broadening inflammatory suppression coverage. The flavonoid quercetin found in Chiricaspi is well-documented to enhance bioavailability of co-administered polyphenols by inhibiting intestinal efflux transporters such as P-glycoprotein, suggesting stacking with curcumin or resveratrol could augment systemic absorption of both agents. These synergy hypotheses are extrapolated from pharmacological class data and have not been tested in combination studies involving C. palanostigma specifically.

## Frequently Asked Questions

### What is chiricaspi used for traditionally?

Chiricaspi is used in Amazonian and Andean folk medicine primarily for wound healing, bone fracture recovery, rheumatic pain, and as a traditional anticancer remedy, with fresh red latex applied directly to affected areas. The name reflects Quechua cultural heritage, and its use is documented across indigenous communities of Peru and Ecuador as a multi-purpose medicinal latex plant.

### Does Croton palanostigma have anticancer properties?

Preclinical in vitro studies demonstrate that C. palanostigma red latex induces apoptosis in cancer cell lines by blocking cells in the late G2/M phase of the cell cycle, disrupting microtubule assembly, and causing chromatin condensation. However, these findings are limited to laboratory cell-line models and have not been validated in animal studies or human clinical trials, so anticancer claims for human use are not supported by current evidence.

### Is chiricaspi safe to take as a supplement?

No standardized supplement form of Chiricaspi exists, and its safety profile has not been formally evaluated in humans. Concerns include the potential presence of phorbol esters, which are toxic at sustained exposures, and enzyme-inhibiting constituents such as pachypodol, which affects mitochondrial ATP synthase; pregnant individuals and those on pharmaceutical medications should avoid this botanical until proper toxicology data are available.

### What are the active compounds in Croton palanostigma?

The primary bioactive compounds identified in C. palanostigma and closely related Croton species include the alkaloid taspine, clerodane and labdane diterpenoids, proanthocyanidins, and flavonoids such as quercetin, myricetin-3-O-rhamnoside, and catechin, along with phenolic acids including gallic acid. Taspine is specifically associated with cytotoxic, anti-inflammatory, and wound-healing activities in the red latex fraction of Croton species.

### What is the difference between chiricaspi and sangre de grado?

Both Chiricaspi (Croton palanostigma) and Sangre de Grado (Croton lechleri) are Amazonian Croton species producing medicinal red latex with overlapping ethnobotanical uses for wounds, inflammation, and anticancer applications. However, C. lechleri has substantially more published research, including informal clinical observations and preclinical melanoma studies, while C. palanostigma has a much smaller evidence base; the two species share chemical constituents including taspine but are distinct botanical entities with potentially different phytochemical profiles.

### What form of chiricaspi is most bioavailable — extract, tincture, or raw latex?

The red latex extract form offers superior bioavailability compared to raw latex, as it concentrates the active alkaloids like taspine in a standardized dose. Tinctures provide good solubility for the alkaloid compounds, though standardized extracts allow for more consistent dosing in clinical research. The traditional form — raw red latex from the trunk — is difficult to standardize and may have variable potency depending on plant maturity and harvest conditions.

### Does chiricaspi interact with chemotherapy or cancer medications?

Because Croton palanostigma exhibits microtubule-disrupting activity similar to some chemotherapy agents in laboratory studies, concurrent use with microtubule-targeting drugs (such as taxanes or vinca alkaloids) should be avoided without medical supervision. There is currently insufficient clinical data to establish safe co-administration protocols, so healthcare providers should be informed before combining chiricaspi with any cancer treatment regimen. More human studies are needed to characterize potential pharmacokinetic or pharmacodynamic interactions.

### How strong is the clinical evidence supporting chiricaspi's anticancer claims?

Current evidence for chiricaspi's anticancer potential is limited to in vitro and preclinical studies demonstrating that its red latex blocks cancer cells in the G2 phase and triggers apoptosis — no human clinical trials have been completed. While the preclinical mechanism is promising, these laboratory results do not translate reliably to human efficacy without controlled clinical testing. Chiricaspi should not be considered a proven cancer treatment until Phase I, II, and III human trials demonstrate safety and efficacy in patients.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*